Wedbush Maintains Outperform on Sutro Biopharma, Lowers Price Target to $12
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst David Nierengarten has maintained an 'Outperform' rating on Sutro Biopharma (NASDAQ:STRO) but lowered the price target from $20 to $12.
August 11, 2023 | 2:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wedbush has maintained an 'Outperform' rating on Sutro Biopharma but lowered the price target from $20 to $12.
The news of a lowered price target by Wedbush could negatively impact investor sentiment towards Sutro Biopharma, potentially leading to a short-term decrease in the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100